Who is this study for: Adult patients with Giant Cell-Rich Tumors
Enrollment Status: Recruiting
Publish Date: August 26, 2019
Intervention Type: Drug
Study Drug: Denosumab
Study Phase: Phase 2
Summary: An open-label, multi-center, phase 2 study of the efficacy of denosumab in subjects with giant cell rich tumors of bone. The population will consist of subjects with the following tumor types: aneurysmal bone cysts (ABC), giant cell granuloma (GCG) and other giant cell rich lesions (primary bone, non-malignant).